Advertisement

Cannabinoids and Pain: Weeding Out Undesired Effects With a Novel Approach to Analgesia

      SEE CORRESPONDING ARTICLE ON PAGE 722
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Booth M.
        Cannabis: A History.
        Thomas Dunne Books, New York2015
        • Boes C.J.
        Osler on migraine.
        Can J Neurol Sci. 2015; 42: 144-147
        • Vowles K.E.
        • McEntee M.L.
        • Julnes P.S.
        • Frohe T.
        • Ney J.P.
        • van der Goes D.N.
        Rates of opioid misuse, abuse, and addiction in chronic pain: A systematic review and data synthesis.
        Pain. 2015; 156: 569-576
        • Rudd R.A.
        Increases in drug and opioid-involved overdose deaths - United States, 2010-2015.
        MMWR Morb Mortal Wkly Rep. 2016; 66: 35
        • Nielsen S.
        • Sabioni P.
        • Trigo J.M.
        • Ware M.A.
        • Betz-Stablein B.D.
        • Murnion B.
        • et al.
        Opioid-sparing effect of cannabinoids: A systematic review and meta-analysis.
        Neuropsychopharmacology. 2017; 42: 1752-1765
        • Woodhams S.G.
        • Chapman V.
        • Finn D.P.
        • Hohmann A.G.
        • Neugebauer V.
        The cannabinoid system and pain.
        Neuropharmacology. 2017; 124: 105-120
        • Zádor F.
        • Wollemann M.
        Receptome: Interactions between three pain-related receptors or the “triumvirate” of cannabinoid, opioid and TRPV1 receptors.
        Pharmacol Res. 2015; 102: 254-263
        • De Aquino J.P.
        • Sherif M.
        • Radhakrishnan R.
        • Cahill J.D.
        • Ranganathan M.
        • D’Souza D.C.
        The psychiatric consequences of cannabinoids.
        Clin Ther. 2018; 40: 1448-1456
        • Khurana L.
        • Mackie K.
        • Piomelli D.
        • Kendall D.A.
        Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities.
        Neuropharmacology. 2017; 124: 3-12
        • Slivicki R.A.
        • Xu Z.
        • Kulkarni P.M.
        • Pertwee R.G.
        • Mackie K.
        • Thakur G.A.
        • Hohmann A.G.
        Positive allosteric modulation of cannabinoid receptor type 1 suppresses pathological pain without producing tolerance or dependence.
        Biol Psychiatry. 2018; 84: 722-733

      Linked Article